Literature DB >> 12067300

Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors.

A Nakata1, K Ogawa, T Sasaki, N Koyama, K Wada, J Kotera, H Kikkawa, K Omori, O Kaminuma.   

Abstract

Even though the existence of phosphodiesterase (PDE) 7 in T cells has been proved, the lack of a selective PDE7 inhibitor has confounded an accurate assessment of PDE7 function in such cells. In order to elucidate the role of PDE7 in human T cell function, the effects of two PDE inhibitors on PDE7A activity, cytokine synthesis, proliferation and CD25 expression of human peripheral blood mononuclear cells (PBMC) were determined. Recombinant human PDE7A was obtained and subjected to cyclic AMP-hydrolysis assay. PBMC of Dermatophagoides farinae mite extract (Df)-sensitive donors were stimulated with the relevant antigen or an anti-CD3 monoclonal antibody (MoAb). PBMC produced IL-5 and proliferated in response to stimulation with Df, while stimulation with anti-CD3 MoAb induced CD25 expression and messenger RNA (mRNA) synthesis of IL-2, IL-4 and IL-5 in peripheral T cells. A PDE inhibitor, T-2585, which suppressed PDE4 isoenzyme with high potency (IC50 = 0.00013 microM) and PDE7A with low potency (IC50 = 1.7 microM) inhibited cytokine synthesis, proliferation and CD25 expression in the dose range at which the drug suppressed PDE7A activity. A potent selective inhibitor of PDE4 (IC50 = 0.00031 microM), RP 73401, which did not effectively suppress PDE7A (IC50 > 10 microM), inhibited the Df- and anti-CD3 MoAb-stimulated responses only weakly, even at 10 microM. PDE7 may play a critical role in the regulation of human T cell function, and thereby selective PDE7 inhibitors have the potential to be used to treat immunological and inflammatory disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12067300      PMCID: PMC1906253          DOI: 10.1046/j.1365-2249.2002.01856.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  50 in total

1.  Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A).

Authors:  K Fujishige; J Kotera; H Michibata; K Yuasa; S Takebayashi; K Okumura; K Omori
Journal:  J Biol Chem       Date:  1999-06-25       Impact factor: 5.157

2.  Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors.

Authors:  D M Essayan; A Kagey-Sobotka; L M Lichtenstein; S K Huang
Journal:  J Pharmacol Exp Ther       Date:  1997-07       Impact factor: 4.030

Review 3.  Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions.

Authors:  S H Soderling; J A Beavo
Journal:  Curr Opin Cell Biol       Date:  2000-04       Impact factor: 8.382

Review 4.  Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme.

Authors:  W J Thompson; W L Terasaki; P M Epstein; S J Strada
Journal:  Adv Cyclic Nucleotide Res       Date:  1979

5.  Regulation of interleukin-13 by type 4 cyclic nucleotide phosphodiesterase (PDE) inhibitors in allergen-specific human T lymphocyte clones.

Authors:  D M Essayan; A Kagey-Sobotka; L M Lichtenstein; S K Huang
Journal:  Biochem Pharmacol       Date:  1997-04-04       Impact factor: 5.858

6.  Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.

Authors:  T Ukita; M Sugahara; Y Terakawa; T Kuroda; K Wada; A Nakata; Y Ohmachi; H Kikkawa; K Ikezawa; K Naito
Journal:  J Med Chem       Date:  1999-03-25       Impact factor: 7.446

7.  Cyclic AMP suppresses interleukin-5 synthesis by human helper T cells via the downregulation of the calcium mobilization pathway.

Authors:  O Kaminuma; A Mori; K Ogawa; H Kikkawa; A Nakata; K Ikezawa; H Okudaira
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

8.  Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin 2 production and down-regulation of transferrin receptor expression.

Authors:  S Chouaib; K Welte; R Mertelsmann; B Dupont
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

Review 9.  Regulation of the immune response by prostaglandins.

Authors:  J S Goodwin; J Ceuppens
Journal:  J Clin Immunol       Date:  1983-10       Impact factor: 8.317

10.  Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A.

Authors:  L Fawcett; R Baxendale; P Stacey; C McGrouther; I Harrow; S Soderling; J Hetman; J A Beavo; S C Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more
  17 in total

Review 1.  Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

Authors:  Adam Lerner; Paul M Epstein
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

2.  Combined use of pharmacophoric models together with drug metabolism and genotoxicity "in silico" studies in the hit finding process.

Authors:  Ma José Jerez; Miguel Jerez; Coral González-García; Sara Ballester; Ana Castro
Journal:  J Comput Aided Mol Des       Date:  2013-01-08       Impact factor: 3.686

Review 3.  Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease.

Authors:  Dave Singh; Simon Lea; Alexander G Mathioudakis
Journal:  Drugs       Date:  2021-11-03       Impact factor: 9.546

4.  Functional characterization of the human phosphodiesterase 7A1 promoter.

Authors:  Mònica Torras-Llort; Fernando Azorín
Journal:  Biochem J       Date:  2003-08-01       Impact factor: 3.857

5.  Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice.

Authors:  Miriam Redondo; Valle Palomo; José Brea; Daniel I Pérez; Rocío Martín-Álvarez; Concepción Pérez; Nuria Paúl-Fernández; Santiago Conde; María Isabel Cadavid; María Isabel Loza; Guadalupe Mengod; Ana Martínez; Carmen Gil; Nuria E Campillo
Journal:  ACS Chem Neurosci       Date:  2012-08-08       Impact factor: 4.418

Review 6.  Therapy for chronic obstructive pulmonary disease in the 21st century.

Authors:  Louise E Donnelly; Duncan F Rogers
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia.

Authors:  Lingzhi Zhang; Fiona Murray; Anja Zahno; Joan R Kanter; Daisy Chou; Ryan Suda; Michael Fenlon; Laura Rassenti; Howard Cottam; Thomas J Kipps; Paul A Insel
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-25       Impact factor: 11.205

8.  Phosphodiesterase 4 and 7 inhibitors produce protective effects against high glucose-induced neurotoxicity in PC12 cells via modulation of the oxidative stress, apoptosis and inflammation pathways.

Authors:  Nazanin Namazi Sarvestani; Saeedeh Saberi Firouzi; Reza Falak; Mohammad Yahya Karimi; Mohammad Davoodzadeh Gholami; Akram Rangbar; Asieh Hosseini
Journal:  Metab Brain Dis       Date:  2018-04-30       Impact factor: 3.584

9.  Functional regulatory T cells produced by inhibiting cyclic nucleotide phosphodiesterase type 3 prevent allograft rejection.

Authors:  Gang Feng; Satish N Nadig; Liselotte Bäckdahl; Stephan Beck; Ross S Francis; Alexandru Schiopu; Andrew Whatcott; Kathryn J Wood; Andrew Bushell
Journal:  Sci Transl Med       Date:  2011-05-18       Impact factor: 17.956

10.  Synthesis, structural analysis, and biological evaluation of thioxoquinazoline derivatives as phosphodiesterase 7 inhibitors.

Authors:  Tania Castaño; Huanchen Wang; Nuria E Campillo; Sara Ballester; Coral González-García; Javier Hernández; Concepción Pérez; Jimena Cuenca; Ana Pérez-Castillo; Ana Martínez; Oscar Huertas; José Luis Gelpí; F Javier Luque; Hengming Ke; Carmen Gil
Journal:  ChemMedChem       Date:  2009-05       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.